J&J Seeks Emergency Use Authorization for its One-Shot COVID-19 Vaccine

Johnson & Johnson (J&J) has applied for an Emergency Use Authorization (EUA)  from the United States Food and Drug Administration (FDA) for its one-shot COVID-19 vaccine, which has shown 66% efficacy in preventing moderate to severe COVID-19 illness. The J&J vaccine may be a game changer in the arduous fight against the novel coronavirus due to the need for only one immunization and the fact that it can be stored at 34° to 46° F. The only COVID-19 vaccines currently available in the US require two shots and sub-zero storage. However, both the Pfizer and Moderna vaccines have higher rates of efficacy (95%) than the J&J immunization. The FDA, along with contracted outside experts, will meet on February 26 to make a decision on the EUA application. Click here to read more.